Abstract
BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.
| Original language | English |
|---|---|
| Pages (from-to) | 383-391 |
| Number of pages | 9 |
| Journal | Familial Cancer |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 3 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cancer Research
- Genetics
- Oncology
- Genetics(clinical)
Cite this
Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation : a case control study. / Segev, Yakir; Rosen, Barry; Lubinski, Jan; Gronwald, Jacek; Lynch, Henry T.; Moller, Pal; Kim-Sing, Charmaine; Ghadirian, Parviz; Karlan, Beth; Eng, Charis; Gilchrist, Dawna; Neuhausen, Susan L.; Eisen, Andrea; Friedman, Eitan; Euhus, David; Ping, Sun; Narod, Steven A.
In: Familial Cancer, Vol. 14, No. 3, 03.04.2015, p. 383-391.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation
T2 - a case control study
AU - Segev, Yakir
AU - Rosen, Barry
AU - Lubinski, Jan
AU - Gronwald, Jacek
AU - Lynch, Henry T.
AU - Moller, Pal
AU - Kim-Sing, Charmaine
AU - Ghadirian, Parviz
AU - Karlan, Beth
AU - Eng, Charis
AU - Gilchrist, Dawna
AU - Neuhausen, Susan L.
AU - Eisen, Andrea
AU - Friedman, Eitan
AU - Euhus, David
AU - Ping, Sun
AU - Narod, Steven A.
PY - 2015/4/3
Y1 - 2015/4/3
N2 - BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.
AB - BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.
UR - http://www.scopus.com/inward/record.url?scp=84941023298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941023298&partnerID=8YFLogxK
U2 - 10.1007/s10689-015-9798-8
DO - 10.1007/s10689-015-9798-8
M3 - Article
VL - 14
SP - 383
EP - 391
JO - Familial Cancer
JF - Familial Cancer
SN - 1389-9600
IS - 3
ER -